Beschreibung:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>To evaluate the early virological response (<jats:styled-content style="fixed-case">EVR</jats:styled-content>) to combined tenofovir‐lamivudine or emtricitabine regimen in <jats:styled-content style="fixed-case">HBV</jats:styled-content>/<jats:styled-content style="fixed-case">HIV</jats:styled-content>‐co‐infected patients and the long‐term efficacy of tenofovir.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this retrospective monocentric study, among the 166 <jats:styled-content style="fixed-case">HIV</jats:styled-content>/<jats:styled-content style="fixed-case">HBV</jats:styled-content>‐co‐infected patients regularly followed from 2003 to 2008 at Bichat Claude Bernard Hospital, 61 patients had received, either <jats:italic>de novo</jats:italic> combination therapy with tenofovir and lamivudine or emtricitabine (group I, <jats:italic>n</jats:italic> = 15) or <jats:italic>add‐on</jats:italic> tenofovir to lamivudine therapy (group II, <jats:italic>n</jats:italic> = 46). The <jats:styled-content style="fixed-case">HBV</jats:styled-content> polymerase region was sequenced and analysed for all patients with available samples.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>All 15 group I patients achieved <jats:styled-content style="fixed-case">EVR</jats:styled-content> vs 32 (82%) of group II patients (<jats:italic>P</jats:italic> = 0.15). Seven adherent group II patients met criteria for primary non‐response, but achieved delayed response (<jats:styled-content style="fixed-case">DR</jats:styled-content>) to therapy. In these seven patients, when compared with the 39 group II patients, there was a trend to longer duration of lamivudine pre‐treatment and to higher rate of lamivudine‐resistant mutants; and <jats:styled-content style="fixed-case">HBV</jats:styled-content> genotype‐G proportion was higher (<jats:italic>P</jats:italic> = 0.026). No virological breakthrough occurred after a median of 46 months follow up.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In these <jats:styled-content style="fixed-case">HBV</jats:styled-content>/<jats:styled-content style="fixed-case">HIV</jats:styled-content>‐co‐infected patients, first‐line <jats:styled-content style="fixed-case">HBV</jats:styled-content> therapy with tenofovir and emtricitabine or lamivudine was associated with <jats:styled-content style="fixed-case">EVR</jats:styled-content>. However, DR to tenofovir was observed in 15% of patients who added tenofovir to lamivudine therapy, of whom four of seven (57%) had genotype G‐<jats:styled-content style="fixed-case">HBV</jats:styled-content> infection. No resistance was evidenced after 46 months of therapy even in patients with DR to tenofovir. At last, a good renal safety profile of <jats:styled-content style="fixed-case">TDF</jats:styled-content> was observed after a median follow‐up of 4 years of therapy.</jats:p></jats:sec>